STATEMENT OF NEED
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School.
TARGET AUDIENCE
Medical oncologists, surgical oncologists, pathologists, nurse practitioners, physician assistants/associates and other healthcare professionals involved in the treatment of patients with soft tissue sarcoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
- Summarize the key clinical, histopathologic, and genomic characteristics that make dedifferentiated liposarcoma unique from other soft tissue sarcoma subtypes
- Assess the benefits and limitations of current molecular testing methodologies for the characterization of soft tissue sarcomas
- Appreciate the role of a multimodality approach in the management of localized dedifferentiated liposarcoma, as well as the current systemic therapy landscape for patients with advanced disease
- Evaluate potential emerging therapies, including MDM2-p53 pathway inhibitors, CDK4/6 inhibitors, and immunotherapeutic approaches, for the treatment of dedifferentiated liposarcoma
REGISTRATION
There is no fee to participate in or claim CME credit for this activity.
JOINTLY ACCREDITED PROVIDER
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS
i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/21/25. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Richard F. Riedel, MD, discloses that he has received grants/research support from Aadi Bioscience, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; and that he has served as a consultant or on an advisory board/panel for Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Inhelheim, Daiichi-Sankyo, Decipheral, GlaxoSmithKline, NanoCarrier, and SpringWorks.
Candace L. Haddox, MD, discloses that she has served as a consultant or on an advisory/board panel for Aadi Bioscience; and that she has received grants/research support from Aadi Bioscience, EMD Serono, Cogent, HiFiBio, Roche, and Tango Therapeutics.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must listen to the podcast and submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
FORMAT
Podcast
CREDIT
0.5 AMA PRA Category 1 Credits™
0.5 AAPA Category 1 CME credits
ESTIMATED TIME TO COMPLETE
30 minutes
DATES AVAILABLE
November 22, 2024 - November 21, 2025
RIchard F. Riedel, MD (Co-Chair)
Richard F. Riedel, MD, is an Associate Professor in the Division of Medical Oncology at Duke University Medical Center and the Associate Director of Clinical and Translational Research for the Duke Sarcoma Program. His clinical practice is dedicated to the care of patients with bone and soft tissue sarcoma, and his research interests lie in identifying novel therapies for these patients. Dr. Riedel is a member of the National Comprehensive Cancer Network (NCCN) Soft Tissue Sarcoma Guidelines Panel member and the NCCN Gastrointestinal Stromal Tumor (GIST) Guidelines Panel, and he is active in educational initiatives for sarcoma treatment.
Candace L. Haddox, MD (Co-Chair)
Candace L. Haddox, MD, is a Physician at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School. She specializes in the treatment of sarcomas, including soft tissue sarcoma, GIST, bone cancers, and uterine sarcoma. Dr. Haddox leads clinical trials in Dana-Farber’s sarcoma group and early phase clinical trials program. Her research focuses on identifying and developing novel targeted therapies and immunotherapies across subtypes of sarcoma and understanding mechanisms of treatment resistance.
Elizabeth H. Baldini, MD, MPH
Elizabeth H. Baldini, MD, MPH, FASTRO, is a Professor of Radiation Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School. She specializes in radiotherapy for sarcoma and thoracic malignancies. Dr. Baldini’s research focuses on prognostic factors for radiation outcomes, patterns of failure among histologic sarcoma subtypes, and development of novel treatment techniques. She is passionate about minimizing local failures and complication rates and developing new strategies for clinical management of sarcomas.
Jason L. Hornick, MD, PhD
Jason L. Hornick, MD, PhD, is a Professor of Pathology at Harvard Medical School and the Director of Surgical Pathology and Immunohistochemistry at Brigham and Women’s Hospital. He specializes in soft tissue sarcoma, gastrointestinal, and endocrine pathology, with expertise in diagnostic immunohistochemistry. Dr. Hornick is passionate about advancing diagnostic surgical pathology by improving tumor classification, defining histologic parameters for outcome prediction, and applying basic biomedical research discoveries to clinical practice.
Vicki L. Keedy, MD, MSCI
Vicki L. Keedy, MD, MSCI, is an Associate Professor of Medicine and the Clinical Director of Sarcoma at Vanderbilt-Ingram Cancer Center. She is also a member of the Phase 1 Clinical Trials Team and serves as the Principal Investigator of multiple trials in soft tissue sarcoma, bone sarcoma, and GIST. Dr. Keedy’s research focuses on the development of novel therapeutics to improve outcomes for patients with these diseases.
Christina L. Roland, MD, MS, FACS
Christina L. Roland, MD, MS, FACS, is an Associate Professor in the Department of Surgical Oncology at MD Anderson Cancer Center. She also serves as Section Chief for Sarcoma Surgery, Vice Chair for Research in the Department of Surgical Oncology, Associate Medical Director of the Sarcoma Center, and Executive Director for Surgery at MD Anderson. Dr. Roland specializes in the surgical treatment of soft tissue sarcoma. She serves as Principal Investigator for multiple clinical trials, and her research focuses on improving multimodality care for patients with soft tissue sarcoma through methods such as novel clinical trial design.
On April 23rd, this panel brought together a multidisciplinary task force of expert faculty members, representing medical oncology, radiation oncology, surgical oncology, and pathology, who will share their insights and provide a consensus opinion on the optimal diagnosis, treatment, and management of soft tissue sarcoma for improving patient outcomes.
During this live discussion hear perspectives on: Clinical presentation of dedifferentiated liposarcoma (DDLPS), the role of oncogenes in the pathogenesis of DDPLS and their significance on prognosis, diagnostic approach to dedifferentiated liposarcoma, including pathology, molecular genetics, and their related challenges and limitations, multidisciplinary team management of disease, highlighting the roles of surgery, radiation, and systemic therapy.
Faculty:
Richard F. Riedel, MD Associate Professor Division of Medical Oncology Duke University Medical Center Candace L. Haddox, MD Physician, Dana-Farber Cancer Institute Instructor in Medicine, Harvard Medical School
Elizabeth H Baldini, MD, MPH, FASTRO Professor of Radiation Oncology Brigham and Women’s Hospital and Dana-Farber Cancer Institute Harvard Medical School
Jason L. Hornick, MD, PhD Professor, Pathology Brigham and Women's Hospital Harvard Medical School
Vicki L. Keedy, MD, MSCI Associate Professor of Medicine Clinical Director, Sarcoma Vanderbilt-Ingram Cancer Center
Christina L. Roland, MD, MS, FACS Associate Professor Department of Surgical Oncology MD Anderson Cancer Center
i3 Health® and Oncology Data Advisor® are pleased to announce the publication of our Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement, in Cancer Treatment Review.
The position statement was authored by the task force comprised of these individuals:
Co-chairs
- Richard F. Riedel, MD, Associate Professor, Division of Medical Oncology, Duke University Medical Center
- Candace L. Haddox, MD, Physician, Dana-Farber Cancer Institute, Instructor in Medicine, Harvard Medical School
Faculty
- Elizabeth H Baldini, MD, MPH, FASTRO, Professor of Radiation Oncology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute Harvard Medical School
- Jason L. Hornick, MD, PhD, Professor of Pathology, Brigham and Women's Hospital Harvard Medical School
- Vicki L. Keedy, MD, MSCI, Associate Professor of Medicine, Clinical Director, Sarcoma, Vanderbilt-Ingram Cancer Center
- Christina L. Roland, MD, MS, FACS, Associate Professor, Department of Surgical Oncology, MD Anderson Cancer Center
"A multidisciplinary approach is critically important in providing the best care for patients with DDLPS. An improved understanding of the molecular underpinnings of the disease has resulted in the use of molecular techniques to aid in the confirmation of the diagnosis, as well as the introduction of novel therapies targeting key signaling pathways involved in its development. Multidisciplinary teams with disease-specific expertise are required to ensure that outcomes for patients are optimized."
